{"id":335227,"date":"2019-11-28T00:00:00","date_gmt":"2019-11-27T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/outlook-on-possible-future-therapy-options\/"},"modified":"2019-11-28T00:00:00","modified_gmt":"2019-11-27T23:00:00","slug":"outlook-on-possible-future-therapy-options","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/outlook-on-possible-future-therapy-options\/","title":{"rendered":"Outlook on possible future therapy options"},"content":{"rendered":"

As part of this year’s AAD, several speakers reported on <\/strong>on research-stage antipsoriatic agents, which showed promising results in phase 2 trials. Biologics and tyrosine kinase 2 inhibitors are among the drugs represented. <\/strong><\/p>\n

Back to “Atopic dermatitis and psoriasis news”.<\/a><\/em><\/strong><\/p>\n

<\/p>\n

In addition to the monoclonal antibody Risankizumab, which was approved this year, several clinical studies on the efficacy and safety of other substances are currently underway, with positive interim results.<\/p>\n

Bimekizumab: good outcomes after 60 weeks<\/h2>\n

The results of the BE ABLE 1 and BE ABLE 2 extension studies indicate great potential of this monoclonal antibody for long-term maintenance therapy, as indicated in the presentation by Dr. Andrew Blauvelt, Oregon Medical Research Center [1]. Bimekizumab is a potent and selective neutralizer of IL-17A and IL-17F, two key proinflammatory cytokines.<\/p>\n

In the 12-week double-blind placebo-controlled phase 2 BE ABLE study 1, bimekizumab resulted in rapid and substantial clinical improvement in moderate to severe plaque psoriasis with a safety profile comparable to previous studies of this agent [2]. Subjects were randomly assigned to experimental conditions and received bimekizumab subcutaneously at 4-week intervals at varying doses: 64 mg, 160 mg, 160 mg with dose escalation to 320 mg, 320 mg, 480 mg, or placebo. Primary endpoint was \u226590% reduction in Psoriasis Area Severity Index (PASI90) at week 12.<\/p>\n

Jeffrey Weinberg, M.D., Icahn School of Medicine, reported phase 2b data for bimekizumab. 50-60% of the highest dose groups achieved PASI 100 at week 12 [2]. In the BE ABLE 2 extension study (n=217), bimekizumab performed well in maintaining complete or near-complete lesion clearance in psoriasis patients over a 60-week period [3]. 80 to 100% of responders (all doses) to BE ABLE 1 showed maintenance of nearly 90% symptom reduction (PASI90) (Fig. 1)<\/strong>. These positive results are currently the longest survey period.  Phase 3 comparative studies of bimekizumab in psoriasis are being conducted based on these results.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n